Table 2.
Univariate association of CDR1-AS and hsa-miR-7 with MFS in the prognostic cohort.
| Clinical parameters | CDR1-AS | hsa-miR-7 | ||||||
|---|---|---|---|---|---|---|---|---|
| n | HR | (95% CI) | P | n | HR | (95% CI) | P | |
| All patients | 345 | 1.02 | (0.90–1.16) | 0.76 | 345 | 1.14 | (1.00–1.30) | 0.043 |
| Hormone receptor/growth factor expression (RT-qPCR)* | ||||||||
| ESR1-negative | 120 | 1.10 | (0.83–1.45) | 0.50 | 120 | 1.03 | (0.77–1.37) | 0.86 |
| ESR1-positive | 225 | 0.98 | (0.84–1.12) | 0.31 | 225 | 1.21 | (1.06–1.38) | 0.006 |
The association of CDR1-AS/hsa-miR-7 expression and MFS in all patients and the patient subgroups based on ESR1 expression is displayed. * Cut-offs for positive and negative hormone receptor/growth factor status were established as previously described56,57. n = number of patients, HR = hazard ratio, CI = confidence interval, and P = p-value. Significant p-values are printed in bold.